Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Other Operating Expenses: 2012-2024

Historic Other Operating Expenses for Amphastar Pharmaceuticals (AMPH) over the last 13 years, with Dec 2024 value amounting to $37.8 million.

  • Amphastar Pharmaceuticals' Other Operating Expenses rose 49.55% to $16.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $49.4 million, marking a year-over-year increase of 25.21%. This contributed to the annual value of $37.8 million for FY2024, which is 31.02% up from last year.
  • Amphastar Pharmaceuticals' Other Operating Expenses amounted to $37.8 million in FY2024, which was up 31.02% from $28.9 million recorded in FY2023.
  • Over the past 5 years, Amphastar Pharmaceuticals' Other Operating Expenses peaked at $37.8 million during FY2024, and registered a low of $14.8 million during FY2020.
  • In the last 3 years, Amphastar Pharmaceuticals' Other Operating Expenses had a median value of $28.9 million in 2023 and averaged $29.4 million.
  • Data for Amphastar Pharmaceuticals' Other Operating Expenses shows a peak YoY skyrocketed of 34.01% (in 2023) over the last 5 years.
  • Over the past 5 years, Amphastar Pharmaceuticals' Other Operating Expenses (Yearly) stood at $14.8 million in 2020, then rose by 18.31% to $17.5 million in 2021, then climbed by 23.13% to $21.5 million in 2022, then soared by 34.01% to $28.9 million in 2023, then spiked by 31.02% to $37.8 million in 2024.